Invention Grant
US09284555B2 Aptazyme capable of selective silencing of target miRNA by releasing an antisense sequence in hepatitis C virus-infected cells and use thereof
有权
能够通过在丙型肝炎病毒感染的细胞中释放反义序列并使用靶蛋白来选择性沉默靶miRNA的Aptazyme
- Patent Title: Aptazyme capable of selective silencing of target miRNA by releasing an antisense sequence in hepatitis C virus-infected cells and use thereof
- Patent Title (中): 能够通过在丙型肝炎病毒感染的细胞中释放反义序列并使用靶蛋白来选择性沉默靶miRNA的Aptazyme
-
Application No.: US13823845Application Date: 2011-09-16
-
Publication No.: US09284555B2Publication Date: 2016-03-15
- Inventor: Seong-Wook Lee , Chang-Ho Lee
- Applicant: Seong-Wook Lee , Chang-Ho Lee
- Applicant Address: KR
- Assignee: Industry-Academic Cooperation Foundation Dankook University
- Current Assignee: Industry-Academic Cooperation Foundation Dankook University
- Current Assignee Address: KR
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: KR10-2010-0091145 20100916
- International Application: PCT/KR2011/006856 WO 20110916
- International Announcement: WO2012/036507 WO 20120322
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12Q1/68 ; C12N15/113 ; C12N15/10
Abstract:
The present invention relates to an aptazyme comprising an aptamer for hepatitis C virus (HCV) RNA-encoding component; a hammerhead ribozyme comprising an antisense sequence to microRNA at the site released by self-cleavage; and a communication module sequence that connects the aptamer and hammerhead ribozyme and triggers a self-cleavage activity of the hammerhead ribozyme upon binding of the aptamer with the HCV RNA-encoding component. The present aptazyme inhibits microRNA activity specifically in HCV proliferating cells and thus a composition of the present invention comprising the aptazyme can be effectively used for treatment of HCV-related diseases.
Public/Granted literature
Information query
IPC分类:
